


BRD73954

Cat. No.:	HY-18700		
CAS No.:	1440209-96-0		
Molecular Formula:	C ₁₆ H ₁₆ N ₂ O ₃		
Molecular Weight:	284.31		
Target:	HDAC		
Pathway:	Cell Cycle/DNA Damage; Epigenetics		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (87.93 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	3.5173 mL	17.5864 mL	35.1729 mL
	5 mM	0.7035 mL	3.5173 mL	7.0346 mL
	10 mM	0.3517 mL	1.7586 mL	3.5173 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution 			

BIOLOGICAL ACTIVITY

Description	BRD73954 is a potent HDAC inhibitor and selectively inhibiting both HDAC6 and HDAC8 with IC ₅₀ values of 0.0036, 0.12, 9, 12, 23 μM for HDAC6, HDAC8, HDAC2, HDAC1 and HDAC3, respectively. BRD73954 decreases the levels of HDAC6, associated with upregulation of Ac-Tubulin ^[1] .		
IC₅₀ & Target	HDAC6 0.036 μM (IC ₅₀)	HDAC8 0.12 μM (IC ₅₀)	HDAC2 9 μM (IC ₅₀)

In Vitro

BRD73954 (10 μ M; 48 h; HeLa cells) inhibits HDAC6 activity via upregulation of Ac-Tubulin^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	HeLa cells
Concentration:	10 μ M
Incubation Time:	48 hours
Result:	Increased α -tubulin acetylation, no change in the acetylation state of H3 was observed.

CUSTOMER VALIDATION

- Acta Pharmacol Sin. 2021 Apr 13.
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
- Patent. US20180263995A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Olson DE, et, al. Discovery of the first histone deacetylase 6/8 dual inhibitors. J Med Chem. 2013 Jun 13;56(11):4816-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA